Health News Releases

  • Today December 21
December 21, 2017 11:15
LMD Welcomes ‘Smartphone-as-Medical-Instrument’ Trend and Highlights Need for Clinical Accuracy
Leman Micro Devices (LMD), the developer of regulated consumer healthcare products that is backed by major players within the mobile device industry, has welcomed news that other companies are enterin
December 12, 2017 14:30
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin)
December 12, 2017 09:30
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against c
December 11, 2017 09:30
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results
December 11, 2017 09:20
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell
December 11, 2017 09:10
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served a
December 08, 2017 17:45
Bertin and Zymo Research Announce New Collaboration
Zymo Research Corp. and Bertin announce a collaboration that ensures the sample lysis step in the microbiome workflow is complete and unbiased. An application note is available describing the material
December 06, 2017 09:45
PMC Group International Announces Acquisition of Pharma Company in France
PMC Group France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of the pharma business of Isochem SAS of France. T
December 04, 2017 14:05
Herbalife Nutrition Appoints Renowned Thai Sports Medicine Expert to Its Nutrition Advisory Board
In helping the world live happier and healthier, premier global nutrition company Herbalife (NYSE:HLF), announced today the appointment of Dr. Korakod Panich, M.D., a sports medicine expert in Thailan
December 04, 2017 11:20
Artemis Hospital Becomes First in India to Adopt Masimo Patient SafetyNet™ Across All Hospital Care Areas
Masimo (NASDAQ: MASI) announced today that Artemis Hospital, one of the leading multi-specialty hospitals in the Delhi-NCR region of India, is adopting Masimo Patient SafetyNet™*, a supplemental remot
December 01, 2017 17:25
Takeda Appoints Toshio Fujimoto, MD, MBA, as General Manager of the Health Innovation Park in Shonan
Takeda Pharmaceutical Company Limited [TSE: 4502] announced today that Toshio Fujimoto, MD, MBA has been appointed General Manager of the Health Innovation Park in Shonan. The appointment is effective
November 29, 2017 08:20
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed into a Phase
November 27, 2017 15:35
Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an Approved Dosing Algorithm
Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women un
November 22, 2017 13:40
Octapharma Donates 30.5 Million International Units of Its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries
2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collabora
November 21, 2017 10:10
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential
Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Th
November 20, 2017 11:00
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal gr
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatmen
November 20, 2017 10:55
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-l
November 17, 2017 09:55
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in pre
November 16, 2017 18:20
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for th
November 15, 2017 18:35
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy
Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions 2017 in Anaheim, California. RE-DUAL PCI™ investigated different treatment approaches i
November 15, 2017 13:20
Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib[1]
AstraZeneca today announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone
November 15, 2017 13:10
New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery
Boehringer Ingelheim announced results from two sub-analyses of the phase III RE-VERSE AD™ study.[1,2] The sub-analyses evaluated the safety and efficacy of idarucizumab (marketed as Praxbind®) in rev
November 14, 2017 18:05
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These res
November 14, 2017 10:05
Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases
Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases i
November 10, 2017 10:09
Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced that more than 1,300 employees are rallying together in support of community service initiatives focused on health, wellness, and education as par
25 per page50 per page75 per page100 per page